- Home
- VSTD vs RDHL Comparison
VSTD vs RDHL Comparison
Compare VSTD & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | RDHL |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | Israel |
| Employees | 259 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.6M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | VSTD | RDHL |
|---|---|---|
| Price | $0.29 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.6K | 21.5K |
| Earning Date | 05-04-2026 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.78 |
| 52 Week High | $2.20 | $3.31 |
Technical Indicators
Market Signals| Indicator | VSTD | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 35.82 |
| Support Level | $0.21 | $0.80 |
| Resistance Level | $0.37 | $1.07 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 19.01 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc.
Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.